Showing 2311-2320 of 3239 results for "".
- DermTech Presents on Value of Decentralization of Clinical Trialshttps://practicaldermatology.com/news/dermtech-presents-on-value-of-decentralization-of-clinical-trials/2461368/Technology can help decentralize clinical trials, leading to greater patient satisfaction, a more diverse patient population, better retention and cost savings, according to a presentation by DermTech at Outsourcing in Clinical Trials Southern California, held from Sept. 28-29 in San Di
- Two New Studies Highlight the Efficacy and Safety Profile of Revance's DAXXIFYhttps://practicaldermatology.com/news/two-new-studies-highlights-the-efficacy-and-safety-profile-of-daxxify/2461360/Glabellar injection of DAXXIFY show a positive effect on eyebrow position and a high response rate and duration of effect ≥24 weeks across all age and race subgroups, according to two new studies in the Aesthetic Surgery Journal. “The newly released pu
- FDA Clears CellFX System for the Treatment of SHhttps://practicaldermatology.com/news/fda-clears-cellfx-system-for-the-treatment-of-sh/2461358/The U.S. Food and Drug Administration (FDA) granted Pulse Bioscience’s CellFX System (FDA) 510(k)marketing clearance for the treatment of sebaceous hyperplasia in patients with Fitzpatrick skin types I-II. This specific indication clearance enhances the CellFX
- Chicken or the Egg? Unravelling the Role of Demodex in Rosaceahttps://practicaldermatology.com/news/chicken-or-the-egg-unravelling-the-role-of-demodex-in-rosacea/2461346/Researchers have long observed that microscopic mites that live as scavengers on normal human skin tend to occur in greater numbers on the faces of rosacea patients. It was unknown, however, whether the higher density of these Demodex, was a cause or an effect of this widespread disease.
- Meet the Cast of Allergan Aesthetics and BOTOX Cosmetic's New 'See Yourself' Campaignhttps://practicaldermatology.com/news/meet-the-cast-of-allergan-aesthetics-and-botox-cosmetics-new-see-yourself-campaign/2461344/Allergan Aesthetics is unveiling the 25 real patients – of all forms, genders, ethnicities and backgrounds – who were selected to participate in the latest iteration of the BOTOX Cosmetic 'See Yourself' campaign. A After receiving nearly 20,000 submis
- Allergan Aesthetics Hits Milestone: 100 Million Syringes of JUVÉDERM Shippedhttps://practicaldermatology.com/news/allergan-aesthetics-hits-milestone-100-million-syringes-of-juvederm-shipped/2461330/Drumroll, please…Allergan Aesthetics, an AbbVie company has produced and shipped 100 million syringes of JUVÉDERM products globally. Since its launch in 2000, the JUVÉDERM Collection of Fillers has grown to where its products are now avail
- FDA Clears LASEROPTEK's HELIOS IV-785 for Aesthetic and Medical Dermatology Usehttps://practicaldermatology.com/news/fda-clears-laseropteks-helios-iv-785-for-aesthetic-and-medical-dermatology-use/2461326/The U.S. Food and Drug Administration has granted 510(k) clearance to LASEROPTEK Co., Ltd.’s HELIOS IV-785 laser system for aesthetic and medical dermatology applications. HELIOS IV-785's novel and synergistic combination of 785nm picosecond photoacoustic effect and 1064 &
- UK Study: Psoriasis Diagnoses in Primary Care Delayed by Up to 5 Yearshttps://practicaldermatology.com/news/uk-study-psoriasis-diagnoses-in-primary-care-delayed-by-up-to-5-years/2461322/Psoriasis may be underdiagnosed in UK primary care settings, according to research out of the University of Manchester in The British Journal of General Practice. Patients who are later diagnosed with psoriasis are twice as likely to be prescribed steroid or antifungal creams t
- New Partnership for Revision Skincare, RVL Pharmaceuticalshttps://practicaldermatology.com/news/new-partnership-for-revision-skincare-rvl-pharmaceuticals/2461320/With a goal to collaborate on a variety of marketing efforts within the medical aesthetics industry, Revision Skincare® and RVL Pharmaceuticals, Inc. the owner of UPNEEQ®, are partnering to address what they see as significant unmet consumer needs. Revisions
- CDC: People with Acne, AD, PsO, and Other Active Exfoliative Skin Conditions at Higher Risk for Severe Monkeypoxhttps://practicaldermatology.com/news/cdc-people-with-acne-ad-pso-and-other-active-exfoliative-skin-conditions-at-higher-risk-for-severe-monkeypox/2461303/People with active exfoliative skin conditions are at higher risk for severe Monkeypox, according to interim clinical guidance from the federal Centers for Disease Control and Prevention. Many people infected with monkeypox virus have a